These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 29944378)
1. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase. Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy. Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619 [TBL] [Abstract][Full Text] [Related]
3. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE. Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241 [TBL] [Abstract][Full Text] [Related]
4. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688 [TBL] [Abstract][Full Text] [Related]
5. RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells. Suthe SR; Yao HP; Weng TH; Wang MH Curr Cancer Drug Targets; 2023; 23(2):103-117. PubMed ID: 36028965 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment. Yao HP; Feng L; Zhou JW; Zhang RW; Wang MH Am J Cancer Res; 2016; 6(5):937-56. PubMed ID: 27293990 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy. Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy. Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells. Li Z; Yao H; Guin S; Padhye SS; Zhou YQ; Wang MH Int J Oncol; 2010 Aug; 37(2):473-82. PubMed ID: 20596675 [TBL] [Abstract][Full Text] [Related]
10. RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy. Yao HP; Hudson R; Wang MH Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188360. PubMed ID: 32234337 [TBL] [Abstract][Full Text] [Related]
11. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells. Yao HP; Zhou YQ; Ma Q; Guin S; Padhye SS; Zhang RW; Wang MH Mol Cancer; 2011 Jul; 10():82. PubMed ID: 21749705 [TBL] [Abstract][Full Text] [Related]
12. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies. Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581 [TBL] [Abstract][Full Text] [Related]
13. RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity. Guin S; Yao HP; Wang MH Mol Pharm; 2010 Apr; 7(2):386-97. PubMed ID: 20039696 [TBL] [Abstract][Full Text] [Related]
14. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450 [TBL] [Abstract][Full Text] [Related]
15. Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics. Padhye SS; Guin S; Yao HP; Zhou YQ; Zhang R; Wang MH Mol Pharm; 2011 Dec; 8(6):2310-9. PubMed ID: 22014215 [TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts. Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403 [TBL] [Abstract][Full Text] [Related]
17. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase. Guin S; Ma Q; Padhye S; Zhou YQ; Yao HP; Wang MH Cancer Chemother Pharmacol; 2011 May; 67(5):1073-83. PubMed ID: 20658288 [TBL] [Abstract][Full Text] [Related]
18. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer. Li Z; Wang M; Yu D; Luo W; Fang J; Huang C; Yao X Cancer Chemother Pharmacol; 2019 Jul; 84(1):61-72. PubMed ID: 31037333 [TBL] [Abstract][Full Text] [Related]
19. hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer. Sun LP; Bai WQ; Zhou DD; Wu XF; Zhang LW; Cui AL; Xie ZH; Gao RJ; Zhen YS; Li ZR; Miao QF J Med Chem; 2023 Nov; 66(21):14700-14715. PubMed ID: 37883180 [TBL] [Abstract][Full Text] [Related]
20. HER2-targeted antibody drug conjugates for ovarian cancer therapy. Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]